Wednesday, October 07, 2026 The Q3 2026 quarterly update for pending CCTG trials with approximate activation timelines are listed below. For more information between the quarterly updates, find the most recent updates and stories of recently opened CCTG trials here: https://www.ctg.queensu.ca/public/trials-development.ALC11 (HEMATOLOGIC) – Expected: Q4 2026Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy ALC9 (HEMATOLOGIC) – Expected: Q4 2026Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE) BI4 (GASTROINTESTINAL) – Expected: Q3 2027Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC) BR39 (LUNG) – Expected: Q4 2026LUNA-2: LND101 in Unresectable Non-small Cell Lung Cancer: A Randomized Phase II Trial EN12 (GYNECOLOGY) – Expected Q1 2027(RAINBO-ORANGE) Treatment of Endometrial Cancer Based on Molecular Features HN14 (HEAD & NECK) – Expected: Q1 2027Delayed Reduced Volume and Dose Elective Radiotherepy (REVERT) in Patients with HNSCC MA42 (BREAST) – Expected: Q1 2027No Chemotherapy in Intermediate-risk HR + HER2 – Early Breast Cancer Treated with Ribociclib (NoLEEta) MD1 (HEMATOLOGIC) – Expected: Q4 2026Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy ME18 (MELANOMA) – Expected: Q3 2027Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3) SR8 (SARCOMA) – Expected: Q2 2027A phase III study of hypofractionated alternative radiation with modulation of neoadjuvant/peri-operative immunotherapy in sarcoma (HARMONY) IND241E (METASTATIC BREAST CANCER) – Expected: Q4 2026A phase II study of CFI-402257 in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancer IND241F (METASTATIC BREAST CANCER) – Expected: Q4 2026A phase II study of CFI-400945 in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancer
